Form 4: Marimed CCO Ryan Crandall Reports Stock Transactions

Marimed Inc.'s Chief Commercial Officer, Ryan Crandall, reported the conversion of restricted stock units into common stock and subsequent tax-related share withholding.

Summary

• Ryan Crandall, Chief Commercial Officer of MARIMED INC. (MRMD), reported transactions involving the company's common stock.
• On March 28, 2026, 6,047 Restricted Stock Units (RSUs) converted into an equal number of common stock shares at a price of $0.
• Following the RSU conversion, 2,096 shares of common stock were disposed of to satisfy tax withholding obligations, at a price of $0.0758 per share.
• After these transactions, Ryan Crandall directly beneficially owns 879,634 shares of common stock.
• The RSUs converted were part of a grant made on March 28, 2024.
• Remaining RSUs from this grant include 6,046 units vesting on September 28, 2026, and 6,047 units vesting on March 28, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It reports a routine insider transaction related to executive compensation and tax obligations, which is an expected part of public company operations and does not indicate any significant positive or negative operational or financial developments.

Positives

• The vesting of Restricted Stock Units (RSUs) indicates a routine compensation event for a key executive, aligning management's interests with shareholders.
• The conversion of RSUs into common stock increases the executive's direct ownership in the company.

Negatives

• No inherently negative aspects are present in this routine insider transaction report.

Future Outlook

The filing indicates future vesting events for Ryan Crandall's Restricted Stock Units, with 6,046 units scheduled to vest on September 28, 2026, and another 6,047 units on March 28, 2027, demonstrating a continued long-term incentive structure for the Chief Commercial Officer.

Industry Context

StockSavvy.ai notes that insider transaction reports like this Form 4 are routine disclosures in the U.S. public markets, providing transparency into executive compensation and ownership changes. While specific to Marimed, such filings are common across all industries and do not inherently reflect broader industry trends or competitive dynamics.

Stakeholder Impact

• Shareholders: Provides transparency regarding executive stock ownership and compensation, which is a standard governance practice.
• Employees: Reflects the company's ongoing executive compensation structure, which may influence broader employee incentive programs.

Next Steps

• 6,046 Restricted Stock Units are scheduled to vest on September 28, 2026.
• 6,047 Restricted Stock Units are scheduled to vest on March 28, 2027.

Key Dates

Keywords

MARIMED, MRMD, Ryan Crandall, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Common Stock, Chief Commercial Officer